The Firm represented OPKO Health, Inc. in acquiring an interest in SciGen (IL) Ltd, an Israeli pharmaceutical company with cGMP facilities.
Baratz & Co is listed by Who's Who Legal as an expert in public procurement law.
Baratz & Co is rated by the "PLC (Practical Law Company) Which Lawyer?" guide as "Highly Recommended" in the field of life sciences, intellectual property and corporate law.
Baratz & Co is listed by the BDI Ranking of Israeli Law Firms for 2012 as highly recommended in the field of Hi Tech.
Baratz & Co is listed by the BDI Ranking of Israeli Law Firms for f 2012 as highly recommended in the field of Capital.
Baratz & Co is recognized by Who's Who Legal as a leader in the area of life sciences legal practice in Israel.
Baratz & Co provides pro bono legal support to ITTN, the Israel Technology Tech Transfer Organization, which unites technology transfer and commercialization offices around Israel.
Baratz & Co, is proud to assist start-up companies and investors through the entire life cycle beginning with seed investments, continuing through commercialization of innovative products, and the formulation of exit strategies and implementation thereof.
Being a part of the start-up nation, the firm further specializes in transactions involving the Israeli Office of the Chief Scientist and other non-dilutive financing sources.
The Firm represented OPKO Health, Inc., a public company traded on the NYSE, controlled by Dr. Phillip Frost, in acquiring FineTech Pharmaceutical Ltd., in consideration of $ 27.5 million in cash and shares of OPKO.
Baratz & Co provides pro bono legal services to Kishorit, a community of adults with special needs.
Baratz & Co provides pro bono legal services to Ofek Le'Yeladenu, a non-profit association of parents of visually impaired and blind children.
The team of Baratz & Co., in collaboration with the nonprofit association "A Different Class" volunteered to teach classes at Nofim elementary school in Tel Aviv.
The firm represented Kahr Medical (2005) Ltd. in an investment transaction within the framework of which Sanofi-Aventis made its first investment in an Israel start-up company.
The firm represented Aecon, Inc. in the $82 million sale of its holdings in the Cross Israel Highway concessionaire.